期刊
HAEMATOLOGICA
卷 105, 期 10, 页码 2358-2367出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2020.247015
关键词
-
类别
资金
- NIH/NCI [SPOREP50CA100707, R01-CA050947, R01CA207237, P01CA155258, R01CA178264]
- Sheldon and Miriam Medical Research Foundation
Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has led to advances in diagnosis, prognosis, and response assessment, and has informed the development of targeted and immune agents. Here we provide an overview of the recent progress in MM, and highlight the most promising research areas to further improve patient outcome in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据